Article Details
Retrieved on: 2022-11-28 18:13:57
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
HANSA BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM THE IMLIFIDASE PHASE 2 STUDY IN ANTIBODY MEDIATED REJECTION (AMR) EPISODES POST KIDNEY ...
Article found on: kalkinemedia.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here